Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Cost of medication-related problems at a university hospital.
- P. Schneider, M. Gift, Y. P. Lee, E. A. Rothermich, B. Sill
- American journal of health-system pharmacy : AJHP…
- 1 November 1995
A review of the medical records of patients for whom an ADR or medication error had been recorded showed a high cost of these events to the institution, with the cost varying with clinical outcome, and a correspondingly strong opportunity for pharmacists to intervene to save money and improve the quality of care. Expand
Prescribing Patterns for Outpatient Treatment of Constipation, Irritable Bowel Syndrome-Related Constipation, and Opioid-Induced Constipation: A Retrospective Cross-Sectional Study.
- K. Trinkley, B. Sill, K. Porter, M. Nahata
- Journal of managed care & specialty pharmacy
- 17 November 2015
Significant changes in treatment categories over time included a decrease in combination therapy for patients aged less than 18 years and an increase in medication monotherapy for all ages, which are in contrast to national recommendations. Expand
Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States
- Catherine Saint-Laurent Thibault, Divya Moorjaney, +4 authors B. Gorsh
- Journal of medical economics
- 20 April 2017
DCV’+ SOF is a dominant option compared with SOF’s+’RBV in the US for the overall GT 3 HCV patient population and was associated with lower costs and better effectiveness in the base case and in almost all scenarios. Expand
Humanistic and economic burden of hepatocellular carcinoma: systematic literature review.
- C. Kohn, Prianka Singh, +5 authors N. Parikh
- The American journal of managed care
- 1 February 2019
The economic and humanistic burden of HCC in the United States is substantial and patients need effective new therapies that prolong survival and positively affect QOL, and healthcare payers need to consider clinical outcomes while balancing economic and QOL implications. Expand
Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy
- M. Bonafede, B. Korytowsky, +5 authors N. Parikh
- Journal of Gastrointestinal Cancer
- 23 April 2019
While no 2L therapy was available during this analysis, recently approved 2L agents have the potential to improve survival after sorafenib failure or intolerance, suggesting a high cost burden. Expand
Prescribing trends for the outpatient treatment of adolescents and young adults with type 2 diabetes mellitus.
The prescribing of pharmacological treatment for type 2 diabetes (T2DM) increased with emphasis on oral agents, while reports of nonpharmacological therapy for T2DM decreased over the 9-year study period with increased use of oral medications in both adolescents and young adults. Expand
Cost Of Treatment-Related Adverse Events (TRAES) In Second-Line (2l) Advanced Hepatocellular Carcinoma (AHCC): Match Adjusted Indirect Comparison (MAIC) Of Nivolumab And Regorafenib
PGI26 FINANCIAL IMPACT OF LIFTING A PRIOR AUTHORIZATION ON LUBIPROSTONE FOR CHRONIC CONSTIPATION PATIENTS IN A COMMERCIAL MANAGED CARE POPULATION (AGE < 65 YEARS)
PDB14 BUDGET IMPACT OF ADDING FIXED-DOSE COMBINATION OF PIOGLITAZONE PLUS GLIMEPIRIDETO A FORMULARY PLAN OVERATHREE-YEARTIME FRAME
years old, and did not have a diagnosis of pregnancy or cancer. Hospitalization attributable to diabetes was defined as admissions due to diabetes, diabetic complications, or cardiovascular diseases.… Expand